FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector
Summit’s Ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US
We haven't written up this one. Financial Times has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.